Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

Core Viewpoint - Arcutis Biotherapeutics, Inc. has launched the "Free to Be Me" awareness campaign featuring professional golfer Max Homa to encourage individuals with seborrheic dermatitis to seek long-term treatment options [1][2]. Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing the needs of individuals with immune-mediated dermatological diseases [13]. - The company has developed ZORYVE, a topical foam treatment for seborrheic dermatitis, which is steroid-free and suitable for various skin types [6][7]. Product Information - ZORYVE foam 0.3% is indicated for treating seborrheic dermatitis in adults and children aged 9 and older [10]. - Clinical trials showed that 77% of individuals using ZORYVE foam achieved clear or almost clear skin after 8 weeks, compared to 53% using an inactive foam [3][4]. - The product provides rapid skin clearance and significant itch relief, with nearly 63% of users reporting significant itch relief at Week 8 [4]. Clinical Efficacy - ZORYVE foam has been recognized for its clinical impact, receiving multiple awards, including the "2025 Best of Beauty Breakthrough Award" from Allure [8]. - The treatment is formulated to be safe and well-tolerated, with common side effects including common cold (1.5%), nausea (1.3%), and headache (1.1%) [5][11]. Campaign Details - The "Free to Be Me" campaign aims to share real experiences of individuals with inflammatory skin conditions to empower them to discuss treatment options with healthcare providers [9].